Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00464074 · ClinicalTrials.gov registry record

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

A clinical trial, sponsored by Biogen.

Completed
Registry status
89
Enrollment target

NCT00464074 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 89 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00464074 has completed, sponsored by Biogen.

COMPLETED
Registry status
89 participants
Enrollment target

Study Summary

This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2007-08-01
Est. Completion 2010-07-31

Sponsor

Biogen

334 total trials

What the Registry Record Tells You About NCT00464074

The ClinicalTrials.gov registry entry for NCT00464074 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00464074 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00464074 about?

NCT00464074 is a clinical study titled "Evaluation of Natalizumab for thE Relief of MS Associated FatiGue". This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.

What is the current status of trial NCT00464074?

This trial is currently completed. The enrollment target is 89 participants. The study started on 2007-08-01. Estimated completion is 2010-07-31.

Who is sponsoring clinical trial NCT00464074?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.